New hope for rare sarcoma: two drugs face off in clinical trial
NCT ID NCT01391962
First seen Feb 02, 2026 · Last updated Jun 19, 2026 · Updated 26 times
Summary
This Phase 2 trial tested two oral drugs, sunitinib and cediranib, in 34 people with a rare, hard-to-treat cancer called alveolar soft part sarcoma that had spread. The drugs work by cutting off the tumor's blood supply. Participants were randomly assigned to one drug, and if their cancer worsened, they could switch to the other. The goal was to see how often tumors shrank and how long they stayed controlled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA, ALVEOLAR SOFT PART are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sunitinib and cediranib (oral drugs that block blood vessel growth to tumors)
What this could lead to
If successful, this trial could identify an effective oral treatment option for a rare sarcoma with no standard therapy, potentially slowing tumor growth.
What could go wrong
This is a small Phase 2 trial with only 34 participants, so results may not apply to all patients. The drugs can cause side effects like fatigue, high blood pressure, and diarrhea.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.